KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Capital Expenditures: 2020-2025

Historic Capital Expenditures for AbCellera Biologics (ABCL) over the last 6 years, with Sep 2025 value amounting to $8.9 million.

  • AbCellera Biologics' Capital Expenditures fell 51.78% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year decrease of 37.10%. This contributed to the annual value of $78.4 million for FY2024, which is 1.88% up from last year.
  • AbCellera Biologics' Capital Expenditures amounted to $8.9 million in Q3 2025, which was down 33.20% from $13.4 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Capital Expenditures ranged from a high of $36.8 million in Q2 2021 and a low of $3.6 million during Q1 2021.
  • For the 3-year period, AbCellera Biologics' Capital Expenditures averaged around $17.1 million, with its median value being $15.6 million (2024).
  • In the last 5 years, AbCellera Biologics' Capital Expenditures soared by 893.90% in 2021 and then crashed by 55.94% in 2025.
  • Quarterly analysis of 5 years shows AbCellera Biologics' Capital Expenditures stood at $9.4 million in 2021, then skyrocketed by 30.75% to $12.3 million in 2022, then climbed by 17.04% to $14.4 million in 2023, then climbed by 8.31% to $15.6 million in 2024, then plummeted by 51.78% to $8.9 million in 2025.
  • Its last three reported values are $8.9 million in Q3 2025, $13.4 million for Q2 2025, and $10.6 million during Q1 2025.